DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.

Sanofi (SNY) and Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has ...

Sanofi to pay $600 million upfront payment to buy Dren Bio's bispecific myeloid cell engager, DR-0201: Paris Friday, March 21, 2025, 09:00 Hrs [IST] Sanofi and Dren Bio, Inc., a p ...

(RTTNews) - Sanofi (SNY), a French pharmaceutical and healthcare company, announced on Thursday that it has entered into a definitive agreement to acquire Dren Bio, Inc.'s DR-0201, a targeted ...

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies, from Dren Bio Inc. for $600 ...

Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bio’s autoimmune disease treatment, DR-0201, reinforcing its expansion in the biopharmaceutical sector. The French healthcare giant ...

We announced entering into an agreement to acquire DR-0201, Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion. The acquisition, subject to closing conditions including receipt ...

In a significant move to bolster its portfolio in autoimmune disease treatments, Sanofi (NASDAQ:SNY) has announced a definitive agreement to acquire DR-0201, a promising bispecific myeloid cell ...